Concert Pharmaceuticals Inc. (NASDAQ: CNCE) stock closed at 8.37 per share at the end of the most recent trading day (a 0.12% change compared to the prior day closing price) with a volume of 9.98M shares and market capitalization of 401.94M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 71 people. Concert Pharmaceuticals Inc. CEO is Roger D. Tung.

The one-year performance of Concert Pharmaceuticals Inc. stock is 200.72%, while year-to-date (YTD) performance is 43.32%. CNCE stock has a five-year performance of -62.5%. Its 52-week range is between 2.66 and 8.44, which gives CNCE stock a 52-week price range ratio of 98.79%

Concert Pharmaceuticals Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 2.69, a price-to-sale (PS) ratio of 12 216.00, a price to cashflow ratio of 3.40, a PEG ratio of 2.32, a ROA of -90.57%, a ROC of -96.72% and a ROE of -116.61%. The company’s profit margin is -%, its EBITDA margin is -292 864.00%, and its revenue ttm is $29.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Concert Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.59 for the next earnings report. Concert Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Concert Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $19, which is 0.00% compared to the current price. The earnings rating for Concert Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Concert Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Concert Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.41, ATR14 : 0.12, CCI20 : 175.24, Chaikin Money Flow : -0.39, MACD : 0.21, Money Flow Index : 65.76, ROC : 0.36, RSI : 66.65, STOCH (14,3) : 21.74, STOCH RSI : 0.12, UO : 27.44, Williams %R : -78.26), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Concert Pharmaceuticals Inc. in the last 12-months were: James V. Cassella (Sold 16 761 shares of value $136 734 ), Jeffrey A. Munsie (Sold 15 148 shares of value $123 266 ), Marc Evan Becker (Sold 15 148 shares of value $123 228 ), Nancy Stuart (Sold 22 141 shares of value $181 574 ), Peter Barton Hutt (Option Excercise at a value of $10 192), Peter Barton Hutt (Sold 3 539 shares of value $21 553 ), Richard H. Aldrich (Buy at a value of $999 999), Roger D. Tung (Sold 9 240 shares of value $66 898 ), Thomas G. Auchincloss (Buy at a value of $28 500), Van Christi Heek (Buy at a value of $49 999)